Status: Recruiting
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Participants needed: 22
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zulfa OmerUpdated: Jan 6, 2026Locations: 1
Eligibility criteria
Diagnosis of CLL or SLL meeting the established 2018 iwCLL diagnostic criteria o... [+10]
Obtaining a CR or nodal PR with no detectable disease in blood or bone marrow af... [+17]